Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Pascasio

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Alimentary Pharmacology & Therapeutics|November 30, 2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)M Buti, J L Calleja, S Lens, et al.
Transplantation Proceedings|November 18, 2008
Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitorsL Barrera Pulido, J M Alamo Martínez, F Pareja Ciuró, et al.
Medicina Clinica|March 31, 1984
[Antibodies against hepatitis B virus in chronic non-alcoholic HBsAg-negative hepatopathies]V F Moreira Vicente, M A Simón Marco, J M Pascasio Acevedo, et al.
Transplantation Proceedings|January 3, 2006
Efficacy and safety of mycophenolate mofetil as part of induction therapy in liver transplantationF Pareja-Ciuró, J Serrano Díez-Canedo, M A Gómez-Bravo, et al.
Revista Clinica Espanola|February 1, 1987
[Prevalence of high ALAT and serologic markers of hepatitis B virus in blood donors incriminated in non-A, non-B posttransfusion hepatitis]J M Pascasio Acevedo, R Bárcena Marugán, C Zamora, et al.
Transplantation Proceedings|November 14, 2006
Scoring guide when deciding to accept an organ for a liver transplantF Pareja-Ciuró, J M Alamo-Martinez, L Barrera-Pulido, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Journal of Viral Hepatitis|October 15, 2014
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients ProgramS Bruno, S Bollani, A L Zignego, et al.
Journal of Viral Hepatitis|December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohortS Alonso, M Riveiro-Barciela, I Fernandez, et al.
Journal of Viral Hepatitis|December 16, 2016
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infectionC Perelló, J A Carrión, B Ruiz-Antorán, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Alimentary Pharmacology & Therapeutics|November 30, 2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)M Buti, J L Calleja, S Lens, et al.
Transplantation Proceedings|November 18, 2008
Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitorsL Barrera Pulido, J M Alamo Martínez, F Pareja Ciuró, et al.
Medicina Clinica|March 31, 1984
[Antibodies against hepatitis B virus in chronic non-alcoholic HBsAg-negative hepatopathies]V F Moreira Vicente, M A Simón Marco, J M Pascasio Acevedo, et al.
Transplantation Proceedings|January 3, 2006
Efficacy and safety of mycophenolate mofetil as part of induction therapy in liver transplantationF Pareja-Ciuró, J Serrano Díez-Canedo, M A Gómez-Bravo, et al.
Revista Clinica Espanola|February 1, 1987
[Prevalence of high ALAT and serologic markers of hepatitis B virus in blood donors incriminated in non-A, non-B posttransfusion hepatitis]J M Pascasio Acevedo, R Bárcena Marugán, C Zamora, et al.
Transplantation Proceedings|November 14, 2006
Scoring guide when deciding to accept an organ for a liver transplantF Pareja-Ciuró, J M Alamo-Martinez, L Barrera-Pulido, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Journal of Viral Hepatitis|October 15, 2014
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients ProgramS Bruno, S Bollani, A L Zignego, et al.
Journal of Viral Hepatitis|December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohortS Alonso, M Riveiro-Barciela, I Fernandez, et al.
Journal of Viral Hepatitis|December 16, 2016
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infectionC Perelló, J A Carrión, B Ruiz-Antorán, et al.
Pageof 5